The Latest Advances and Guidance in Nonmetastatic Castration-Resistant Prostate Cancer

In this episode, Karim Fizazi, MD, PhD, and Alicia K. Morgans, MD, MPH, discuss the clinical implications of the latest data on androgen receptor–targeting agents in the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). Topics include:Updated safety and patient preference data from the ARAMIS and ODENZA trialsChoice of apalutamide, darolutamide, and enzalutamideCounseling patients on adverse eventsManaging patients with asymptomatic nonmetastatic CRPCPresenters:Karim Fizazi, MD, PhDFull ProfessorCancer MedicineGustave RoussyVillejuif, France  Alicia K. Morgans, MD, MPHAssociate ProfessorDivision of OncologyDepartment of MedicineNorthwestern UniversityChicago, Illinois  Link to full program, including downloadable slides:https://bit.ly/36IEnNE Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.